1-(1-苯并噻吩-2-基)哌啶 | 40584-57-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 1-(1-苯并噻吩-2-基)哌啶
• 英文名称: 1-(benzo[b]thiophen-2-yl)piperidine
• 英文别名: 2-(piperidin-1-yl)-1-benzothiophene；2-(piperidino)benzothiophene；1-benzo[b]thiophen-2-yl-piperidine；1-Benzo[b]thiophen-2-yl-piperidin；2-Piperidinbenzothiophen；1-(1-Benzothiophen-2-yl)piperidine
• CAS: 40584-57-4
• 化学式: C₁₃H₁₅NS
• 分子量: 217.335
• InChiKey: DZVADPDEULVABU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  31.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1-苯并噻吩-2-基)哌啶 以 四氢呋喃 、 氯苯 为溶剂， 生成 (4-Bromophenyl)-[2-(4-methoxyphenyl)-1-benzothiophen-3-yl]methanone
  参考文献：
  名称：

  Synergistic methodologies for the synthesis of 3-aroyl-2-arylbenzo[b]thiophene-based selective estrogen receptor modulators. Two concise syntheses of raloxifene

  摘要：

  Difunctionalized benzo[b] thiophene intermediates are prepared which allow fully independent elaboration of the 2-aryl position or the tether position of benzo[b]thiophene-based selective estrogen receptor modulators (SERMs). Two concise syntheses of the SERM raloxifene (Evista(R)) are presented. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)00955-7
• 作为产物：
  描述：

  2'-bromoacetophenone ethoxycarbonylhydrazone 在 copper(l) iodide 、 氯化亚砜 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1-(1-苯并噻吩-2-基)哌啶
  参考文献：
  名称：

  A Convenient Approach to 2-Aminobenzo[b]chalcogenophenes Based on Copper-Catalyzed Transformation of 4-(2-Bromophenyl)-1,2,3-chalcogenodiazoles in the Presence of a Base and Amines

  摘要：

  The reactions of 4-(2-bromophenyl)-1,2,3-thia-and -selenadiazoles with amines in the presence of potassium carbonate and copper(I) iodide afforded 2-aminobenzo[b]chalcogenophenes. The corresponding thiaand selenamides, prepared by interaction of 4-(2-bromophenyl)-1,2,3-thia- and -selenadiazoles with amines in the absence of copper salt, were transformed into 2-aminobenzo[b]chalcogenophenes by the action of potassium carbonate and copper(I) iodide in DMF in different yields.

  DOI：

  10.1134/s1070363218040126

文献信息

• Copper- and Cobalt-Catalyzed Syntheses of Thiophene-Based Tertiary Amines
  作者：Salima Bouarfa、Simon Graßl、Maria Ivanova、Timothy Langlais、Ghenia Bentabed-Ababsa、Frédéric Lassagne、William Erb、Thierry Roisnel、Vincent Dorcet、Paul Knochel、Florence Mongin

  DOI：10.1002/ejoc.201900276

  日期：2019.6.2

  Both copper‐ and cobalt‐catalyzed aminations of arylzincs using N‐benzoyloxy amines are possible. Thus, thienylzincs prepared by transmetalation from thienylmagnesium halides obtained by various methods including deprotometalation were aminated with success. In addition, triarylamines were prepared from aminothiophenes by consecutive copper‐catalyzed N‐arylations using iodoarenes.

  使用N-苯甲酰氧基胺的铜和钴催化的芳基锌的胺化反应都是可行的。因此，通过由包括去原金属化的各种方法获得的由噻吩基镁卤化物通过重金属化制备的噻吩基锌被成功地胺化。此外，使用碘代芳烃通过连续的铜催化的N-芳基化反应，由氨基噻吩制备了三芳基胺。
• 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake
  申请人：ELI LILLY AND COMPANY

  公开号：EP0812826A1

  公开（公告）日：1997-12-17

  The pharmaceutical use of novel compounds of formula I: where Z is a structure of formula A-B is -C=CH- or -C(R5)-CH2-; X is S or NR4; R1 is H, halo, formyl, C1-C4 alkyl, C1-C4 alkoxy, thienylmethyloxy, 4,5-dihydrothiazol-2-yl, cyano, nitro, carboxamido, trifluoromethyl or hydroxy; R2 is H or halo; R3 is H, C1-C4 alkyl, (C1-C4 alkylene)-aryl, or -CH2-Y-NR7R8; R4 is H, C1-C4 alkyl, C1-C5 acyl, or phenylsulfonyl; R5 is H or OH; R6 is H or methyl; Y is -CH2- or -C(O)-; R7 is pyridinyl; and R8 is H or -C(O)-(C3-C6 cycloalkyl); and pharmaceutically acceptable salts thereof.

  化合物的药用途：其中Z是formulaA-B结构，-C=CH-或-C(R5)-CH2-；X是S或NR4；R1是H、卤素、甲酰基、C1-C4烷基、C1-C4烷氧基、噻吩甲氧基、4,5-二氢噻唑-2-基、氰基、硝基、羧酰胺基、三氟甲基或羟基；R2是H或卤素；R3是H、C1-C4烷基、(C1-C4烷基)-芳基，或-CH2-Y-NR7R8；R4是H、C1-C4烷基、C1-C5酰基，或苯基磺酰基；R5是H或OH；R6是H或甲基；Y是-CH2-或-C(O)-；R7是吡啶基；R8是H或-C(O)-(C3-C6环烷基)；以及其药用上可接受的盐。
• Ground State Generation and Cyclization of Aminium Radicals in the Formation of Tetrahydroquinolines
  作者：Cassie Pratley、Sabine Fenner、John A. Murphy

  DOI：10.1021/acs.orglett.4c00179

  日期：2024.2.16

  This paper reports the first examples of ground state radical-mediated intramolecular C–H amination to afford 1-methyl-1,2,3,4-tetrahydroquinolines from N-2,4-dinitrophenoxy derivatives of arylpropylamines. Whereas the photoactivation of N-2,4-dinitrophenoxyamines for intermolecular reactions has been established, ground state chemistry provides the desired cyclization products in moderate to excellent

  本文报道了基态自由基介导的分子内 C-H 胺化的第一个例子，从芳基丙胺的N -2,4-二硝基苯氧基衍生物得到 1-甲基-1,2,3,4-四氢喹啉。虽然用于分子间反应的N -2,4-二硝基苯氧基胺的光活化已经建立，但基态化学在酸性条件下使用 Ru(bpy) 3 Cl 2 （42-95% 产率）以中等至优异的产率提供了所需的环化产物。空气气氛。
• Inhibition of serotonin reuptake
  申请人：ELI LILLY AND COMPANY

  公开号：EP1077213A2

  公开（公告）日：2001-02-21

  The pharmaceutical use of novel compounds of formula I: where Z is a structure of formula A-B is -C=CH- or -C(R5)-CH2-; X is S or NR4; R1 is H, halo, formyl, C1-C4 alkyl, C1-C4 alkoxy, thienylmethyloxy, 4,5-dihydrothiazol-2-yl, cyano, nitro, carboxamido, trifluoromethyl or hydroxy; R2 is H or halo; R3 is H, C1-C4 alkyl, (C1-C4 alkylene)-aryl, or -CH2-Y-NR7R8; R4 is H, C1-C4 alkyl, C1-C5 acyl, or phenylsulfonyl; R5 is H or OH; R6 is H or methyl; Y is -CH2- or -C(O)-; R7 is pyridinyl; and R8 is H or -C(O)-(C3-C6 cycloalkyl); and pharmaceutically acceptable salts thereof.

  式 I 的新型化合物的药物用途： 式中 Z 为式结构 A-B是-C=CH-或-C(R5)-CH2-； X 是 S 或 NR4； R1 是 H、卤素、甲酰基、C1-C4 烷基、C1-C4 烷氧基、噻吩基甲基氧基、4,5-二氢噻唑-2-基、氰基、硝基、羧酰胺基、三氟甲基或羟基； R2 是 H 或卤代 R3 是 H、C1-C4 烷基、(C1-C4 亚烷基)-芳基或-CH2-Y-NR7R8； R4 是 H、C1-C4 烷基、C1-C5酰基或苯磺酰基； R5 是 H 或 OH R6 是 H 或甲基； Y 是-CH2-或-C(O)-； R7 是吡啶基；以及 R8 是 H 或-C(O)-(C3-C6 环烷基)；及其药学上可接受的盐。
• Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)- 4(3H)-azaquinazolinones
  申请人：——

  公开号：US20010051627A1

  公开（公告）日：2001-12-13

  This invention relates to compounds which are generally alpha 1A/B -receptor antagonists and which are represented by Formula I: 1 wherein the substituents are as defined in the specification; or pharmaceutically acceptable salts, hydrates, or N-oxides thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and a process for their preparation.

  本发明涉及的化合物一般为 alpha 1A/B -受体拮抗剂，由式 I 表示： 1 其中取代基如说明书中所定义；或其药学上可接受的盐、水合物或 N-氧化物。本发明还涉及含有此类化合物的药物组合物、将其用作治疗剂的方法及其制备工艺。